TABLE V.
Baseline characteristics of selected randomized controlled trials for the acute treatment of cancer-associated thrombosis
| Characteristic | Reference (study name) | |||||||
|---|---|---|---|---|---|---|---|---|
| Lee et al., 200311 (CLOT) | Lee et al., 201514 (CATCH) | Raskob et al., 20187 (HOKUSAI VTE Cancer) | Young et al., 20188 (SELECT-D) | |||||
| Anticoagulant | Dalteparin | Warfarin | Tinzaparin | Warfarin | Edoxaban | Dalteparin | Rivaroxaban | Dalteparin |
| Age (years) | 62 | 63 | 59.7 | 58.8 | 64.3 | 63.7 | 67 | 67 |
| Metastatic cancer (%) | 66 | 68.6 | 66 | 63.3 | 52.4 | 53.4 | 58 | 58 |
| Cancer therapy (%) | 78.7 | 76.6 | 50.8 | 55 | 71.6 | 63.1 | 69 | 70 |
| ECOG PS 2 (%) | 34.9 | 36.1 | 23.6 | 22.8 | 23.6 | 23.7 | 26 | 21 |
| Top 3 cancer types | Breast Colorectal Lung |
Gynecologic Colorectal Upper GI |
Colorectal Lung Genitourinary |
Colorectal Lung Breast |
||||
ECOG PS = Eastern Cooperative Oncology Group performance status; GI = gastrointestinal.